New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany
source: unsplash.com

New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany

According to a story from Benzinga, the pharmaceutical company Inceptua Group has recently announced that the medicine paclitaxel micellar (marketed as Apealea) is now available in Germany. This medication is…

Continue Reading New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany
ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint
source: pixabay.com

ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint

  Findings from the MITO23 Trial investigating the outcome of the chemotherapy drug trabectedin against physician’s choice to treat BRCA-mutated patients with ovarian cancer were presented at ASCO’s 2022 Annual…

Continue Reading ICYMI: Trabectedin for Ovarian Cancer Did Not Meet its Primary Endpoint

China Conditionally Approves Pamiparib for Those with Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

BeiGene has just announced that China has given conditional approval to Pamiparib, a PARP inhibitor used as a therapy for BRCA associated ovarian cancer, fallopian tube cancer, and primary peritoneal…

Continue Reading China Conditionally Approves Pamiparib for Those with Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Pamiparib for Ovarian, Fallopian, and Peritoneal Cancers Receives Conditional Approval in China
Sourced from Pixabay

Pamiparib for Ovarian, Fallopian, and Peritoneal Cancers Receives Conditional Approval in China

In China, the Conditional Approval process allows for new drugs to be marketed and developed based on an urgent and unmet need. For example, drugs which treat patients with rare…

Continue Reading Pamiparib for Ovarian, Fallopian, and Peritoneal Cancers Receives Conditional Approval in China